Research Article

Dexmedetomidine Preconditioning Protects Rats from Renal Ischemia–Reperfusion Injury Accompanied with Biphasic Changes of Nuclear Factor-Kappa B Signaling

Naren Bao, Bing Tang, and Junke Wang

Department of Anesthesiology, Hospital of China Medical University, 155 Nanjingbei Street, Heping District, Shenyang, Liaoning 110001, China

Correspondence should be addressed to Junke Wang; wangjunke45@126.com

Received 7 March 2020; Accepted 30 March 2020; Published 17 April 2020

Guest Editor: Wenkai Ren

Copyright © 2020 Naren Bao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute kidney injury (AKI) is one of the most common and troublesome perioperative complications. Dexmedetomidine (DEX) is a potent α2-adrenoceptor (α2-AR) agonist with anti-inflammatory and renoprotective effects. In this study, a rat renal ischemia–reperfusion injury (IRI) model was induced. At 24 h after reperfusion, the IRI-induced damage and the renoprotection of DEX preconditioning were confirmed both biochemically and histologically. Changes in nuclear factor-kappa B (NF-κB), as well as its downstream anti-inflammatory factor A20 and proinflammatory factor tumor necrosis factor-α (TNF-α), were detected. Atipamezole, a nonselective antagonist, was then added 5 min before the administration of DEX to further analyze DEX’s effects on NF-κB, and another anti-inflammatory medicine, methylprednisolone, was used in comparison with DEX, to further analyze DEX’s effects on NF-κB. Different concentrations of DEX (0 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM) were applied to preincubated human renal tubular epithelial cell line (HK-2) cells in vitro. After anoxia and reoxygenation, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay and enzyme-linked immunosorbent assay (ELISA) were performed to evaluate the levels of NF-κB downstream anti-inflammatory cytokines. The results showed that, unlike methylprednisolone, DEX preconditioning led to a time-dependent biphasic change (first activation then inhibition) of NF-κB in the rat renal IRI models that were given 25 μg/kg i.p. It was accompanied by a similarly biphasic change of TNF-α and an early and persistent upregulation of A20. In vitro, DEX’s cellular protection showed a concentration-dependent biphasic change which was protective within the range of 0 to 100 nM but became opposite when concentrations are greater than 1 μM. The changes in the A20 and NF-κB messenger RNA (mRNA) levels were consistent with the renoprotective ability of DEX. In other words, DEX preconditioning protected the rats from renal IRI via regulation biphasic change of NF-κB signaling.

1. Introduction

Acute kidney injury (AKI) is one of the most common and troublesome complications in hospitalized patients after surgery, hemorrhagic shock, cardiac arrest, and sepsis [1, 2]. AKI is not merely single-organ dysfunction related to endothelial injury, cellular apoptosis, and oxidative stress; it also causes inflammatory reactions involving neutrophil migration and cytokine release. This can result in damage to the extrarenal organs, such as the lung, heart, liver, and brain, and it can often lead to significant increases in mortality, hospital stays, and medical-related costs [3–6]. According to the Kidney Disease: Improving Global Outcomes (KDIGO) definition, AKI leads to complications in 18.3% of all hospitalized patients and 57% of critically ill patients, with an associated in-hospital mortality of 11% and 27%, respectively [7, 8].

A major pathological process in AKI, kidney ischemia–reperfusion injury (IRI), is an inflammatory reaction in which the nuclear factor-kappa B (NF-κB) family plays a key role [9–15]. Dexmedetomidine (DEX), a potent α2-adrenoceptor (α2-AR) agonist that is widely used perioperatively, has been recently found to have protective and anti-inflammatory effects on organs [16–20]. The mechanisms...
underlying DEX’s renal protection could include the inhibition of NF-κB and its downstream proinflammatory factor [21, 22]. Interestingly, α2-ARs are classic guanosine triphosphate (GTP) protein-coupled receptors (GPCR). Their agonists are coupled primarily with the inhibitory subunits (Gi). This leads to the inhibition of downstream adenylate cyclase (AC), followed by the inhibition of cyclic adenosine monophosphate (cAMP), and, eventually, the activation of NF-κB signaling [23–25]. By now, the specific connection between DEX and NF-κB signaling has yet to be elucidated. And many researches on the possible protective or damaging effects of α2-AR agonism are inconclusive [26, 27]. It seems that there are multiple, and sometimes paradoxical, relationships among NF-κB, α2-AR agonism, and organ protection.

In order to determine how α2-AR agonism participates in the changes of NF-κB signaling while generating renal protective effects, we established a classic rat renal ischemia–reperfusion model to observe the fluctuations in NF-κB signaling at different time points after IRI. Comparisons of the effects of methylprednisolone, an NF-κB inhibitor and anti-inflammatory agent, facilitated the determination of possible correlations. Second, the study examined the effects of different doses (subclinical, clinical, or much larger doses) of DEX on the possible relationship to the changes in NF-κB signaling and cell survival.

2. Materials and Methods

2.1. Animals. The experimental protocols were performed in accordance with the Guide for the Care and Use of Laboratory Animals of China Medical University. They were approved by the China Medical University Ethics Review Committee for Animal Experimentation (Shenyang, Liaoning, China). Healthy male 7–8-week-old Sprague-Dawley rats weighing 220–270 g were housed under pathogen-free conditions. The animals were acclimatized to the laboratory conditions (22 °C ± 1 °C, 12–12 h light–dark cycle, and ad libitum access to food and water) for 1 week prior to the experiment, and they were fasted 24 h before the operation.

2.2. Renal Ischemia–Reperfusion Injury Model. Renal IRI was induced by right renal pedicle clamping for 45 min and left nephrectomy under 1.5% isoflurane surgical anesthesia. The successful restoration of blood perfusion was indicated by the change in the color of the kidney from dark purple to reddish brown within 5 min of the release of the arterial clip. After the incision was sutured, 0.2% ropivacaine was administered subcutaneously. The rectal temperatures were maintained at 37°C ± 1°C with a heating pad. The heart rates were monitored with subcutaneous electrodes. A 24 G trocar was placed in each left femoral artery to monitor invasive arterial pressure. The exclusionary criteria were a mean blood pressure (MAP) lower than 55 mmHg or a heart rate slower than 200 beats per min (bpm) for more than 5 min. Each animal received an i.p. injection of 0.5 mL saline every 2 h until it awoke or until the specimen was collected.

2.3. Experimental Protocol. The rats were randomly assigned to six groups (Figure 1). Group 1, the S (sham) group: bilateral renal pedicle dissection was performed without renal vessel occlusion. Group 2, the I (IRI) group: the rats underwent left renal resection and right renal artery clamping for 45 min. Group 3, the D+I (DEX preconditioning) group: the rats received 25 μg/kg DEX i.p. (on the basis of previous studies [28]) 30 min before the establishment of renal IRI. Group 4, A+D+I (antagonist) group: the α2-AR antagonist atipamezole (250 μg/kg) was injected i.p. 5 min before the administration of 25 μg/kg DEX and the establishment of renal IRI 30 min later. Group 5, D (DEX) group: the rats received 25 μg/kg DEX i.p., and 30 min later, they underwent the same operation as those in the S group. Group 6, M+I (methylprednisolone preconditioning) group: the rats received 30 mg/kg methylprednisolone i.p. 30 min before the establishment of renal IRI.

2.4. Renal Function Assessment. Twenty-four hours after reperfusion, five animals in each group (S, I, D+I, A+D+I, D, and M+I) underwent systemic heparinization (200 U/kg) and blood sample acquisition. In addition, the blood was centrifuged at 3,000 rpm for 10 min at 4°C. The supernatant was numbered and preserved at −70°C for the assessment of creatinine (Cr) and urea nitrogen (BUN) with a biochemical analyzer.

3. Histological Study

Five animals in each group were sacrificed 24 h after the reperfusion or sham operations. The kidney was collected from each rat and fixed in neutral formaldehyde solution for 24 h before being immered in a phosphate buffered saline (PBS) solution. The tissues were embedded in paraffin, cut into 5 μm sections, and stained with hematoxylin and eosin (HE) for light microscopy. Renal damage was evaluated against the modified criteria described by Paller et al. [29]. Five nonrepeating visualization fields were observed under ×400 magnification, and 10 renal tubules were scored in each field of view.

3.1. Nuclear Factor-Kappa B p65 Signaling Analysis by Western Blot. First, the NF-κB p65 signaling in Groups I and D+I were compared at 1, 3, 6, and 24 h after IRI. This allowed for the time point at which the greatest changes in NF-κB p65 signaling were observed to be the basis for the comparisons of the groups (S, I, D+I, A+D+I, D, and M+I). The rats were sacrificed at different time points.

The kidneys were homogenized, and the nuclear and cytoplasmic extracts from each specimen were purified through the use of nucleoprotein and cytoplasmic protein extraction kits (KGP-150; Kangchen, Shanghai, China). The manufacturer’s instructions were followed. The samples were separated through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto a nitrocellulose membrane. Subsequently, the membrane was blocked with 5% nonfat milk at room temperature for 2 h. This was followed by overnight incubation with rabbit polyclonal anti-NF-κB p65 antibody (1:500, 8242S, Cell Signaling Technology, USA), rabbit anti-TNF-α antibody (1:500, ab6671, Abcam, USA), rabbit polyclonal anti-A20/TNFAIP3.
antibody (1 : 500, 5630S, Cell Signaling Technology, USA), or rabbit polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1 : 500, Santa Cruz, USA). The membranes were then washed and incubated with a secondary antibody, goat anti-rabbit HRP-conjugated IgG (1 : 4,000, Cell Signaling Biotechnology, USA), for 2 h. The blotted protein bands were visualized with enhanced chemiluminescence (ECL) western blot detection reagents (Amersham, USA). The band density measurements were correlated with protein expression and normalized to the GAPDH band density.

3.2. Immunohistochemistry for Detection of Nuclear Factor-Kappa B p65 and A20.

One hour after reperfusion or the sham operation, each rat was transcardially perfused with cold saline under deep anesthesia. The right renal pedicle was separated, and the kidney was removed after the kidney capsule was gently peeled off. The kidney was then cut to two parts. One part was fixed in 4% paraformaldehyde overnight, and the other was stored at −70°C for further western blot analysis. After gradient dehydration, the tissues were immersed in liquid paraﬃn and embedded prior to the preparation of 5 μm thick paraﬃn sections. Next, the paraﬃn sections were dewaxed to water, rinsed with distilled water, and soaked in PBS for 5 min. To eliminate endogenous peroxidase activity, 3% hydrogen peroxide (H₂O₂) was incubated at room temperature for 5 to 10 min. The primary antibody, NF-κB p65 (1 : 500, Cell Signaling Technology, USA, 8242S), and A20 (1 : 300, Abcam, ab13597) were added dropwise and incubated at 37°C for 1 to 2 h. Reagent 1 (polymer helper) was added, and this was followed by incubation at room temperature or 37°C for 20 to 30 min.

After each of the aforementioned steps, the sections were rinsed with PBS three times for 2 min. The developer (diaminobezidine, DAB) was then added. The sections were fully rinsed with tap water, counterstained, dehydrated and sealed, and then photographed. The A20 protein, which is expressed mainly in the cytoplasm, appears as brownish yellow granules; NF-κB p65 protein, which is expressed in the cytoplasm and/or nucleus, appears as brownish yellow granules.

3.3. In Vitro Experiments

3.3.1. Cell Culture and Hypoxia Reoxygenation. Human renal proximal tubular epithelial cells (HK-2, Chinese Academy of Medical Sciences) were cultured and passaged every 3 to 4 days in 100 mm dishes containing RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich). The cells were incubated in a humidified atmosphere of 5% CO₂ and 95% air at 37°C for 24 hours and subcultured at 70–80% confluence. For the experiments, the HK-2 cells were plated onto 60 mm dishes in a medium containing 10% fetal bovine serum for 24 h. They were then switched to RPMI-1640, a serum-free medium, for 24 hours. At the end of treatment, the cells were harvested for further analysis.

After overnight adhesion, the cells were treated with media containing DEX. To facilitate the detection of time-dependent effects, the cells were treated for 30 min. At the end of incubation, the drug-containing medium was replaced with 0.1 mL DEX-free RPMI-1640, and 0.5 mg/mL MTT was added to each well prior to 4 h of incubation.

3.4. Cell Viability. Cell viability was determined through an MTT assay. The HK-2 cells were plated into 96-well
plates at a density of $5 \times 10^4$ cells/well and incubated with 0.5 mg/mL MTT (Sigma-Aldrich, St. Louis, MO) for 3 h. They were then centrifuged at 1,800 rpm at room temperature for 10 min to remove the supernatant. Subsequently, for-mazan was extracted from the pelleted cells with 600 mL of dimethyl sulfoxide (DMSO) for 15 min. The optical density (OD) was measured on an enzyme-linked detector, and the detection wavelength was 490 nm. Each treatment was set up with 2–8 replicate wells with a blank control. Cell viability was calculated on the basis of the OD:

$$\text{OD} = \frac{\text{OD of normal culture cells} - \text{OD of hypoxic cultured cells}}{\text{OD of blank control}}$$

3.5. Real-Time Reverse Transcription Polymerase Chain Reaction Detection of A20 and Nuclear Factor-Kappa B Messenger RNA. Reverse transcription polymerase chain reaction (RT-PCR) analysis of total RNA and then cDNA were prepared from cultured cells through the use of TRIzol reagent (Invitrogen Life technology, USA) and a PrimeScript™ RT reagent Kit (Takara, Japan). The following primers were used: human NF-κB p65, upstream: 5′-CTTCTTGCCTCCTA CAGAGGTC-3′, downstream: 5′-GAGCAGTCTGTTGCA CTGTG-3′; human A20 (TNFAIP3), upstream: 5′-CACAC AAGGACTTGGATC-3′, downstream: 5′-CTGTAGTCCTT TGGAAGCAAGTACTG-3′; and human GAPDH, upstream: 5′-CCAGGCGCCCATCTACGACCTAAA-3′, downstream: 5′- TTCTTTTGCTGGTCGACGCCAG-3′. Real-time PCR was performed in a 96-well optical reaction plate; SYBR Premix Ex Taq™ (Takara, Japan) was used. The real-time PCR reactions were performed on Agilent Mx3000P QPCR systems (Agilent, CA).

3.6. Selection of Hypoxia Duration. The HK-2 cells were placed in an incubator containing 5% CO$_2$ and 1% O$_2$ for 0, 1, 2, 3, or 6 h. The shortest hypoxic time for more than 50% of the cells that died was selected on the basis of the changes in cell activity (MTT assay) as a follow-up test condition.

3.7. Dexmedetomidine Concentrations for Human Renal Proximal Tubular Epithelial Cell Incubation. The HK-2 cells were treated with different DEX concentrations (0 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, or 10 μM), and this was followed with hypoxia–reoxygenation. Cell activity A20 and NF-κB p65 messenger RNA (mRNA) levels were observed.

3.8. Statistical Analysis. All statistical analyses were performed in IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, NY, USA). The histological scores, which are presented as medians (interquartile ranges), were analyzed with the Kruskal–Wallis test. The quantitative data are presented as the means ± standard deviations (SDs). Multiple comparisons of the groups were analyzed through the use of one-way repeated-measures analysis of variance (ANOVA) with the Bonferroni post hoc tests. Differences were considered statistically significant at $p < 0.05$.

4. Results

4.1. Dexmedetomidine Preconditioning Provided Renoprotective Effects. At 24 h after reperfusion, the IRI group (Group I) exhibited obvious kidney damage, with an increase in the BUN levels ($p < 0.01$ vs. Group S). As is shown in Table 1, DEX preconditioning significantly mitigated the deterioration of BUN ($p < 0.01$ vs. Group I), and this could be completely reversed by atipamezole ($p < 0.01$ vs. Groups D+I and S; $p > 0.05$ vs. Group I). The methylprednisolone preconditioning yielded effects that were similar to but less protective than those observed for DEX ($p < 0.01$ vs. Group I; $p < 0.05$ vs. Group S). Similar results were observed for the Cr levels. The Group D values were normal (Table 1).

The histopathological assessment of tubular damage was conducted by an investigator who was blinded to the experimental protocol. The junction of the renal cortex and medulla was observed under a light microscope. IRI (Group I) caused significant pathological injury ($p < 0.01$ vs. Group S), including obvious renal tubule dilatation, swollen or flat tubular epithelial cells, and various types of degeneration, shedding, and necrosis of these cells (Figure 2). DEX (Group D+I) significantly reduced renal IRI. Microscopically, the overall renal tubular structure was relatively complete. There was only a slight expansion of the tubular lumen. There was no signiﬁcant difference between these results and those for DEX.

4.2. Dexmedetomidine Preconditioning Led to a Time-Dependent Biphasic Change (First Activation Then Inhibition) of NF-κB. To determine the changes in the NF-κB signaling underlying the renoprotective effects of DEX at different time points, renal tissues were collected from Groups I and D+I at 1, 3, 6, and 24 h after reperfusion ($n = 5$ per group) for western blot and compared with those from Group S. First, at each time point, NF-κB nuclear transfer was found to be significantly higher in Groups I and D+I than in Group S ($p < 0.05$ vs. Group S). DEX led to a time-dependent biphasic
change of NF-κB that at the first activation (within 3 h especially at 1 h after IRI) then inhibition (1 h, \( p < 0.01 \); and 3 h, \( p < 0.05 \) vs. Group I) at 6 h and 24 h after reperfusion, the NF-κB in Group D+I was similar to that in Group I (\( p > 0.05 \) vs. Group I; Figure 3).

4.3. Dexmedetomidine Preconditioning Continuously Increased A20 Expression and Temporarily Increased and Then Significantly Inhibited TNF-α Expression. The analysis of the NF-κB downstream anti- and proinflammatory proteins (A20 and TNF-α) at the same time points after reperfusion indicated that IRI led an moderate increase in A20 which peaks at 3 h after reperfusion. DEX preconditioning advanced the peak to 1 h after reperfusion (\( p < 0.01 \) vs. Group S) and remained at a high level thereafter (\( p < 0.05 \) at each time point vs. Group S; Figure 3).

The results for the important proinflammatory cytokine TNF-α were even more interesting. First, the TNF-α levels in Groups I and D+I were significantly higher than those observed in Group S (\( p < 0.05 \) vs. Group S). However, Group D+I showed a biphasic change of temporarily upregulated (\( p < 0.05 \) vs. Group S) and then significantly downregulated (\( p < 0.05 \) vs. Group S) levels of TNF-α which was similar to the changes observed with NF-κB. This suggested a return to the anti-inflammatory conditions that were consistent with the above-described renoprotective effects of DEX (at 6 h, \( p < 0.05 \); and at 24 h, \( p < 0.01 \) vs. Group I).

4.4. Comparisons of Nuclear Factor-Kappa B Signaling at 1 Hour after Reperfusion. Because the most obvious changes in NF-κB signaling were observed within 1 h of IRI, this time point was selected for the comparisons of the six groups (S, I, D+I, A+D+I, D, and M+I). DEX preconditioning was found
were consistent changes in the NF-κB signaling pathway, with a time-dependent biphasic change of NF-κB of the early activation (within 3 h of IRI) and later inhibition (6 h after IRI) of NF-κB signaling in the rat renal IRI models that were given 25 μg/kg i.p. (c) It was accompanied by the early (<3 h) upregulation and later (>6 h) significant inhibition of TNF-α and (d) the persistent upregulation of A20. The data are the mean ± standard deviation (SD; n = 5). *p < 0.05, **p < 0.01 vs. S; #p < 0.05, ##p < 0.01 vs. I.

4.5. Dexmedetomidine Preconditioning Showed a Concentration-Dependent Biphasic Change in Cell Protection Which Was Positively Correlated with the Nuclear Factor-Kappa B and A20 Variations. As was previously explained, the in vivo changes in the NF-κB signaling pathway, with or without the application of DEX preconditioning, were observed along a time axis. Next, the in vitro effects of the different DEX concentrations on the NF-κB signaling pathway were observed.

First, the most appropriate hypoxia time for the experiments by MTT assay was determined. Cell viability decreased significantly to 37% ± 9.2% (>50%) after 3 h of hypoxia (p < 0.01 vs. control group without hypoxia 98% ± 1.7%). Extending the hypoxia time to 6 h did not significantly change the cell survival rate (31% ± 4.1%, p > 0.05 vs. 3 h hypoxia). Therefore, 3 h was identified as the hypoxia duration for the subsequent experiments. A median concentration (100 nM) was selected for testing DEX preconditioning for different durations (30 min, 1 h, 2 h, and 3 h) before hypoxia exposure. The MTT assay helped to confirm that the best and shortest DEX preincubation time was 1 h. The cell survival rate was 85% (p < 0.01 vs. the nonincubated
Group). Reoxygenation for 1 h was chosen for all of the in vitro experiments.

After DEX preconditioning at different concentrations (0 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, or 10 μM) for 1 h, the HK-2 cells were subjected to hypoxia–reoxygenation, and cell viability was compared. Within a range of 0 to 100 nM, cell survival was positively correlated with the DEX concentration. It increased from 36% ± 6% (0 nM) to 77% ± 9% (100 nM). When the concentration of DEX was increased to 1 μM, cell viability did not improve further (p > 0.05 vs. the 100 nM group). DEX preincubation at 10 μM even led to decreases in cell viability (p < 0.05 vs. the 100 nM group). The changes in cell viability were positively correlated with the variations in NF-κB and A20 (Figure 7).

5. Discussion

The study yielded two new findings. First, unlike the methylprednisolone application, DEX preconditioning exhibited a biphasic change of NF-κB (activated NF-κB within 3 h of IRI and inhibited NF-κB 6 h after IRI) in the rat renal IRI models that were given 25 μg/kg DEX i.p. It was accompanied by the early and persistent upregulation of A20 and early upregulation of TNF-α and significant inhibition in the later period. Second, in vitro, DEX also showed a biphasic cellular protection that was positively concentration-dependent within the range of 0 to 100 nM (clinical doses) but negatively correlated with the concentration when it was greater than 1 μM. The changes in the NF-κB and A20 mRNA levels were consistent with the renoprotective ability of DEX. Thus, DEX preconditioning protected the rats from renal IRI via the fine regulation of NF-κB signaling.

The unexpected findings that DEX preconditioning (25 μg/kg i.p.) led to biphasic change of NF-κB p65 signaling are different from those of previous studies. The following might be the reasons. First, there were differences in the observation time points in this study and previous studies [22, 30]. Few studies have observed changes in NF-κB signaling in early reperfusion (especially within 3 h). Second, the differences in the experimental animals, organs, and doses and modes of DEX administration (i.p. or i.v., pre- or postconditioning) led to the variations in α2-AR agonism, α2-AR expression levels, and, eventually, changes in NF-κB [22, 30–32]. Whether NF-κB activation is an indication of organ damage or protection should not be concluded as merely being...
either good or bad. Indeed, the NF-κB signaling system provides protection from extraneous challenges. Unfortunately, the protection afforded by NF-κB-induced gene expression was not without a cost: the induction of local and systemic inflammation. The reason was that the downstream cytokines of NF-κB included not only anti-inflammatory molecules (e.g., A20 and CYLD) but also proinflammatory molecules (e.g., chemokines, cytokines, and adhesion molecules) [33–35].

The systemic inhibition of NF-κB by various methods has been found to ameliorate IRI. However, there are two aspects to the activation of NF-κB: damage and protection. In ischemic pre- or postconditioning and drug preconditioning, NF-κB is also responsible for tissue protection against IRI [36–42]. Specifically, the severity and duration of ischemia determine the outcomes for IRI [15]. Mild or brief ischemia causes the moderate activation of NF-κB and promotes the formation of cytoprotective complexes. Severe or long-term ischemia leads to the strong activation of NF-κB; the release of a large number of inflammatory factors; the recognition of Toll-like receptor (TLR), monocytes, or macrophages infiltration; and, eventually, the production of IRI.
In addition, an interesting result was that TNF-α initially increased within 3 h of DEX preconditioning and decreased significantly after 6 h. In this study, the early temporary increase of NF-κB and TNF-α played a protective role. This is indicative of their possible involvement in the balance of inflammation. The mechanism was similar to that in ischemic preconditioning [38, 43]. Thus, it is possible that the maintenance of moderate NF-κB activity in the early stage of inflammation or the inhibition of NF-κB activation in the case of out-of-control inflammation could be both effective and noncontradictory.

In the first part of the present study, the effects of methylprednisolone and DEX were compared. Both methylprednisolone and DEX provided renoprotective effects during renal IRI even though they produced opposite changes in NF-κB activation and TNF-α and A20 protein expression. This again demonstrated the duality of the physiological role of NF-κB.

The findings provide an indication of a likely more elaborate but not well-understood underlying mechanism in DEX. The findings were interpreted in terms of the relationship between the GTP protein-coupled receptors and NF-κB. G protein-coupled receptors (GPCRs) are widely distributed in the human body. They play an active role in regulating transcription and a variety of cellular functions. GPCRs use several possibly nonclassic pathways to activate NF-κB [23, 24]. The aberrant regulation of the GPCR or NF-κB signaling axis leads to the development of many diseases, such as cancer, inflammation, and autoimmunity. The α2-ARs are classic GPCR proteins. The inhibition of AC through G_i is the main signal transduction mechanism in all α2-AR subtypes [24]. On the one hand, it inhibits the AC-cAMP-PKA pathway directly through the G_αi proteins and suppresses the phosphorylation of the cAMP response element-binding protein (CREB) [35, 44]. On the other hand, the G_β and G_γ subunits dissociate from G_αi and activate the
phosphatidylinositol 3-kinase- (PI3K-) protein kinase B (AKT) pathway, phospholipase C, extracellular regulated protein kinases (ERK), and p38 mitogen-activated protein kinase (p38MAPK) [23, 44–47]. Both pathways eventually lead to the activation of NF-κB [23]. Therefore, the activation of NF-κB, even temporarily, should be a reasonable result of DEX’s excitation of the α2-ARs.

More interesting, the findings on the possible protective or damaging effects of α2-AR agonism are inconclusive [26, 27]. One study found that the application of DEX after myocardial infarction increased myocardial injury [48]. Gu et al. suggested that the organ-protective effects of DEX postconditioning are less than those of preconditioning [32]. Bunte et al. found that postconditioning with DEX was concentration-dependent in the range of 0.3 to 3 nM. Concentrations greater than 3 nM did not further enhance this cardioprotective effect [49]. It seems that there are multiple, and sometimes paradoxical, relationships between α2-AR agonism and organ protection. We speculate that different doses and timing of DEX treatment may be responsible for this. Further study should be made to get a better understanding.

Several previous studies have reported on the biphasic responses of AC or cAMP to α2-AR agonism during inflammation [24, 26, 50–52]. The findings indicated that α2-AR has inhibitory and stimulatory components. First, different α2-AR subtype agonists couple with Gi to inhibit AC to the same extent. However, if given high concentrations of agonist or high receptor expression, α2-ARs couple both physically and functionally with Gi and activate AC with a clear ranked order of α2A > α2B > α2C. Thus, with the gradual increase in the agonist concentrations, AC is first inhibited and then stimulated, and vice versa. Therefore, it is possible that the temporary activation of NF-κB in the present study might be associated with the effects of DEX on AC. The reason is the changes in α2-AR expression accompanied by the inflammation caused by IRI or the changes in the plasma concentrations over time. A review of the literature indicates that this is the first evidence of the specific actions between DEX and NF-κB.

Second, another new in vitro finding was the concentration-dependent biphasic effects of DEX on cell viability. Within 0 to 100 nM, cell viability, NF-κB mRNA, and A20 mRNA were positively correlated with the DEX concentrations. When it exceeded 1 μM, the NF-κB mRNA, the A20 mRNA levels and cell viability began to decrease. Coincidentally, Lai et al. [42] found that with increases in DEX concentrations from 10 nM to 100 μM, there were biphasic increases and then decreases in inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, IL-1β, and IL-6. Nishina et al. [53] noted that DEX caused neutrophil apoptosis when the clinically relevant dose was exceeded.

The optimal DEX concentration observed in both the present study and Lai et al.’s study was in the range of 10 to 100 nM [42], and this was consistent with the clinical dose range. Fraser et al. also found that at low concentrations (1–100 nM), epinephrine attenuated forskolin-stimulated cAMP accumulation in a receptor density-dependent manner and increased the cAMP levels at concentrations above 100 nM [50]. Therefore, all the results indicate that it is possible that DEX might be simultaneously coupled with Gi and Gi when preconditioned in the renal IRI in the in vivo and in vitro models. This results in time- and concentration-dependent biphasic changes in NF-κB signaling.

In recent years, A20 has been found to have a protective effect in renal IRI. This occurs through the control of endogenous injury and the maintenance of the balance between pro- and anti-inflammatory responses [54–56]. It has been predicted that A20 will be one of the targets in the prevention and treatment of AKI and chronic kidney disease. In the in vivo phase of the present study, DEX preconditioning was found to continuously upregulate A20 expression in vitro and during perfusion. The A20 mRNA levels under different concentrations of DEX were consistent with the changes in the cell survival rate. This confirms the importance of A20 in the protection of DEX. DEX’s effects on non-IRI rats were observed. In addition, the mild upregulation of A20 was found not to be harmful. Whether A20 is the key to the protective effects of DEX needs further study.

In sum, the results of this study indicate that DEX preconditioning does provide renal protection; however, the timing and dosage range might need to be carefully considered. Given that DEX could increase NF-κB, it could cause organ damage and even increase the likelihood of cancer recurrence and metastasis [57, 58]. Further research is required to determine the α2-AR subtype responsible for the changes in NF-κB signaling; the renoprotection of DEX postconditioning; and the role of G proteins, NF-κB, and A20 in the process.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors of this manuscript declare there is no conflict of interest.

Acknowledgments

This work was supported by Science and Technology Research Project of Liaoning Provincial Education Department (LK201651).

References

[1] K. Doi and H. Rabb, “Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets,” Kidney International, vol. 89, no. 3, pp. 555–564, 2016.
[2] O. Rewa and S. M. Bagshaw, “Acute kidney injury-epidemiology, outcomes and economics,” Nature Reviews. Nephrology, vol. 10, no. 4, pp. 193–207, 2014.
[3] A. J. Lewington, J. Cerda, and R. L. Mehta, “Raising awareness of acute kidney injury: a global perspective of a silent killer,” Kidney International, vol. 84, no. 3, pp. 457–467, 2013.
[4] A. S. Levey and M. T. James, “Acute kidney injury,” *Annals of Internal Medicine*, vol. 167, no. 9, pp. ITC66–ITC80, 2017.

[5] S. A. Lee, M. Cozzi, E. L. Bush, and H. Rabb, “Distant organ dysfunction in acute kidney injury: a review,” *American Journal of Kidney Diseases*, vol. 72, no. 6, pp. 846–856, 2018.

[6] L. Yang, G. Xing, L. Wang et al., “Acute kidney injury in China: a cross-sectional survey,” *Lancet*, vol. 386, no. 10002, pp. 1465–1471, 2015.

[7] X. Zeng, G. M. McMahon, S. M. Brunelli, D. W. Bates, and S. S. Waiker, “Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals,” *Clinical Journal of the American Society of Nephrology*, vol. 9, no. 1, pp. 12–20, 2014.

[8] E. A. Hoste, S. M. Bagshaw, R. Bellomo et al., “Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study,” *Intensive Care Medicine*, vol. 41, no. 8, pp. 1411–1423, 2015.

[9] K. K. Meldrum, K. Hile, D. R. Meldrum, J. A. Crane, J. P. Gearhart, and A. L. Burnett, “Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism,” *The Journal of Urology*, vol. 168, no. 1, pp. 248–252, 2002.

[10] N. H. Lameire, A. Bagga, D. Cruz et al., “Acute kidney injury: an increasing global concern,” *Lancet*, vol. 382, no. 9887, pp. 170–179, 2013.

[11] K. k. Donnahoo, d. r. Meldrum, r. shenkar, c.-s. chung, e. abraham, and a. h. Harken, “Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney,” *The Journal of Urology*, vol. 163, no. 4, pp. 1328–1332, 2000.

[12] M. A. R. C. Daemen, B. de Vries, and W. A. Buurman, “Apoptosis and inflammation in renal reperfusion injury,” *Transplantation*, vol. 73, no. 11, pp. 1693–1700, 2002.

[13] A. B. Sanz, M. D. Sanchez-Niño, A. M. Ramos et al., “NF-kappaB in renal inflammation,” *Journal of the American Society of Nephrology*, vol. 21, no. 8, pp. 1254–1262, 2010.

[14] J. M. Thurman, “Triggers of inflammation after renal ischemia/reperfusion,” *Clinical Immunology*, vol. 123, no. 1, pp. 7–13, 2007.

[15] H. R. Jang and H. Rabb, “The innate immune response in ischemic acute kidney injury,” *Clinical Immunology*, vol. 130, no. 1, pp. 41–50, 2009.

[16] T. Taniguchi, Y. Kidani, H. Kanakura, Y. Takemoto, and K. Yamamoto, “Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats,” *Critical Care Medicine*, vol. 32, no. 6, pp. 1322–1326, 2004.

[17] S. Hofer, J. Stepan, T. Wagner et al., “Central sympatholytics prolong survival in experimental sepsis,” *Critical Care*, vol. 13, no. 1, p. R11, 2009.

[18] M. Tasdogan, D. Memis, N. Sut, and M. Yuksel, “Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis,” *Journal of Critical Anesthesia*, vol. 21, no. 6, pp. 394–400, 2009.

[19] H. Qiao, R. D. Sanders, D. Ma, X. Wu, and M. Maze, “Sedation improves early outcome in severely septic Sprague Dawley rats,” *Critical Care*, vol. 13, no. 4, p. R136, 2009.

[20] F. Ji, Z. Li, H. Nguyen et al., “Perioperative dexmedetomidine improves outcomes of cardiac surgery,” *Circulation*, vol. 127, no. 15, pp. 1576–1584, 2013.

[21] Y. Yao, X. Hu, X. Feng et al., “Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting the NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway,” *Journal of Cellular Biochemistry*, vol. 120, no. 10, pp. 18509–18523, 2019.

[22] H. Yao, X. Chi, Y. Jin et al., “Dexmedetomidine Inhibits TLR4/NF-κB Activation and Reduces Acute Kidney Injury after Orthotopic Autologous Liver Transplantation in Rats,” *Scientific Reports*, vol. 5, no. 1, p. 16849, 2015.

[23] R. D. Ye, “Regulation of nuclear factor kappaB activation by G-protein-coupled receptors,” *Journal of Leukocyte Biology*, vol. 70, no. 6, pp. 839–848, 2001.

[24] M. G. Eason, H. Kurose, B. D. Holt, J. R. Raymond, and S. B. Liggitt, “Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C adrenergic receptors to Gi and Gs,” *The Journal of Biological Chemistry*, vol. 267, no. 22, pp. 15795–15801, 1992.

[25] K. Pohjanoksa, C. C. Jansson, K. Luomala, A. Marjamäki, J. M. Savola, and M. Scheinm, “Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase,” *European Journal of Pharmacology*, vol. 335, no. 1, pp. 53–63, 1997.

[26] D. Ma, N. Rajakumaraswamy, and M. Maze, “α2-Adrenoceptor agonists: shedding light on neuroprotection?,” *British Medical Bulletin*, vol. 71, no. 1, pp. 77–92, 2005.

[27] M. Miksa, P. Das, M. Zhou et al., “Pivotal role of the alpha(2A)-adrenoceptor in producing inflammation and organ injury in a rat model of sepsis,” *PLOS One*, vol. 4, no. 5, p. e5504, 2009.

[28] Y. Si, H. Bao, I. Han et al., “Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation,” *Journal of Translational Medicine*, vol. 11, no. 1, p. 141, 2013.

[29] M. S. Paller, J. R. Hoidal, and T. F. Ferris, “Oxygen free radicals in ischemic acute renal failure in the rat,” *The Journal of Clinical Investigation*, vol. 74, no. 4, pp. 1156–1164, 1984.

[30] X. Chi, X. Wei, W. Gao et al., “Dexmedetomidine ameliorates acute lung injury following orthotopic autologous liver transplantation in rats probably by inhibiting Toll-like receptor 4-nuclear factor kappa B signaling,” *Journal of Translational Medicine*, vol. 13, no. 1, p. 190, 2015.

[31] Y. Wang, S. Wu, X. Yu et al., “Dexmedetomidine protects rat liver against ischemia-reperfusion injury partly by the α2A-Adrenoceptor subtype and the mechanism is associated with the TLR4/NF-κB pathway,” *International Journal of Molecular Sciences*, vol. 17, no. 7, p. 995, 2016.

[32] J. Gu, P. Sun, H. Zhao et al., “Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice,” *Critical Care*, vol. 15, no. 3, p. R153, 2011.

[33] D. E. Nelson, A. E. Ichikawa, M. Elliott et al., “Oscillations in NF-kappaB signaling control the dynamics of gene expression,” *Science*, vol. 306, no. 5696, pp. 704–708, 2004.

[34] N. Shembade, A. Ma, and E. W. Harhai, “Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes,” *Science*, vol. 327, no. 5969, pp. 1135–1139, 2010.

[35] M. S. Hayden and S. Ghosh, “Signaling to NF-kappaB,” *Genes & Development*, vol. 18, no. 18, pp. 2195–2224, 2004.

[36] L. W. Chen, L. Egan, Z. W. Li, F. R. Greten, M. F. Kagnoff, and M. Karin, “The two faces of IKK and NF-kappaB inhibition:...
prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion,” *Nature Medicine*, vol. 9, no. 5, pp. 575–581, 2003.

[37] S. Kuboki, T. Okaya, R. Schuster et al., "Hepatocyte NF-kappaB activation is hepatoprotective during ischemia-reperfusion injury and is augmented by ischemic hypothermia," *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 292, no. 1, pp. G201–G207, 2007.

[38] A. Iida, H. Yoshidome, T. Shida et al., "Hepatocyte nuclear factor-kappa beta (NF-kappaB) activation is protective but is decreased in the cholestatic liver with endotoxiaemia," *Surgery*, vol. 148, no. 3, pp. 477–489, 2010.

[39] B. Dawn, Y. Guo, A. Rezazadeh et al., “Tumor necrosis factor-alpha does not modulate ischemia-reperfusion injury in naive myocardium but is essential for the development of late preconditioning,” *Journal of Molecular and Cellular Cardiology*, vol. 37, no. 1, pp. 51–61, 2004.

[40] S. Jiang, J. Streeter, B. M. Schickling, K. Zimmerman, R. M. Weiss, and Miller FJ Jr, "Noxi NADPH oxidase is necessary for late but not early myocardial ischemic preconditioning," *Cardiovascular Research*, vol. 102, no. 1, pp. 79–87, 2014.

[41] Y. T. Xuan, X. L. Tang, S. Banerjee et al., “Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits,” *Circulation Research*, vol. 84, no. 9, pp. 1095–1109, 1999.

[42] Y. C. Lai, P. S. Tsai, and C. J. Huang, "Effects of dexmedetomidine on regulating endothoxin-induced up-regulation of inflammatory molecules in murine macrophages," *The Journal of Surgical Research*, vol. 154, no. 2, pp. 212–219, 2009.

[43] T. Lawrence, D. W. Gilroy, P. R. Colville-Nash, and D. A. Willoughby, "Possible new role for NF-kappaB in the resolution of inflammation," *Nature Medicine*, vol. 7, no. 12, pp. 1291–1297, 2001.

[44] A. Lymeropoulos, G. Karkoulis, W. J. Koch, and C. S. Flor dellis, "Alpha2-adrenergic receptor subtype-specific activation of NF-kappaB in PC12 cells," *Neuroscience Letters*, vol. 402, no. 3, pp. 210–215, 2006.

[45] D. M. Rosenbaum, S. G. F. Rasmussen, and B. K. Kobilka, “The structure and function of G-protein-coupled receptors,” *Nature*, vol. 459, no. 7245, pp. 356–363, 2009.

[46] A. V. Smrcka and I. Fisher, "G-protein beta subunits as multifunctional scaffolds and transducers in G-protein-coupled receptor signaling," *Cellular and Molecular Life Sciences*, vol. 76, no. 22, pp. 4447–4459, 2019.

[47] H. de Castro Abrantes, M. Briquet, C. Schmuziger et al., “The lactate receptor HCAR1 modulates neuronal network activity through the activation of Gaand Gβγ Subunits,” *The Journal of Neuroscience*, vol. 39, no. 23, pp. 4422–4433, 2019.

[48] S. Mimuro, T. Katoh, A. Suzuki et al., “Deterioration of myocardial injury due to dexmedetomidine administration after myocardial ischaemia,” *Resuscitation*, vol. 81, no. 12, pp. 1714–1717, 2010.

[49] S. Bunte, F. Behmenburg, N. Majewski et al., "Characteristics of dexmedetomidine postconditioning in the field of myocardial ischemia-reperfusion injury," *Anesthesia and Analgesia*, vol. 130, no. 1, pp. 90–98, 2020.

[50] C. M. Fraser, S. Arakawa, W. McCombie, and J. C. Venter, “Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylylate cyclase attenuation and activation,” *The Journal of Biological Chemistry*, vol. 264, no. 20, pp. 11754–11761, 1989.

[51] D. J. Pepperl and J. W. Regan, “Selective coupling of alpha 2-adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells,” *Molecular Pharmacology*, vol. 44, no. 4, pp. 802–809, 1993.

[52] K. A. Meller, J. Calka, M. Kaczmarek, and B. Jana, “Expression of alpha and beta adrenergic receptors in the pig uterus during inflammation,” *Theriogenology*, vol. 119, pp. 96–104, 2018.

[53] K. Nishina, H. Akamatsu, K. Mikawa et al., “The effects of clonidine and dexmedetomidine on human neutrophil functions,” *Anesthesia and Analgesia*, vol. 88, no. 2, pp. 452–458, 1999.

[54] J. Lutz, L. A. Luong, M. Strobl et al., “The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation,” *Journal of Molecular Medicine (Berlin, Germany)*, vol. 86, no. 12, pp. 1329–1339, 2008.

[55] C. G. da Silva, E. R. Maccariello, S. W. Wilson et al., “Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-kappaB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation,” *Journal of Cellular Physiology*, vol. 227, no. 4, pp. 1382–1390, 2012.

[56] U. Kunter, S. Daniel, M. B. Arvelo et al., “Combined expression of A1 and A2A achieves optimal protection of renal proximal tubular epithelial cells,” *Kidney International*, vol. 68, no. 4, pp. 1520–1532, 2005.

[57] H. Lavon, P. Matzner, A. Benbenishty et al., “Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers,” *British Journal of Anaesthesia*, vol. 120, no. 1, pp. 188–196, 2018.

[58] L. Wang, W. Zhou, Y. Zhong et al., “Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-xB signaling pathway,” *Molecular Cancer*, vol. 16, no. 1, p. 61, 2017.